Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity

Molecular Pharmacology

Volumn 54, Issue 2, 1998, Pages 291-297

  Miller, Michael D ^a   Lamy, Patrick D ^a   Fuller, Michael D ^a   Mulato, Andrew S ^a   Margot, Nicolas A ^a   Cihlar, Tomas ^a   Cherrington, Julie M ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE EXPRESSION; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS REPLICATION;

EID: 0031848831     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.54.2.291     Document Type: Article

References (40)

1. Arion D, Borkow G, Gu Z, Wainberg MA, and Parniak MA (1996) The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase. J Biol Chem 271:19860-19864.
2. Arts EJ, Li X, Gu Z, Kleiman L, Parniak MA, and Wainberg MA (1994) Comparison of deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template-switching reaction. J Biol Chem 269:14672-14680.
3. Back NKT, Nijhuis M, Keulen W, Boucher CAB, Oude-Essink BB, van Kuilenburg ABP, van Gennip AH, and Berkhout B (1996) Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 15:4040-4049.
4. Balzarini J, Nave JF, Becker MA, Tatibana M, and De Clercq E (1995) Kinetic properties of adenine nucleotide analogues against purified 5-phosphoribosyl-1-pyrophosphate synthetases from E. coli, rat liver, and human erythrocytes. Nucleosides Nucleotides 14:1861-1871.
5. Boyer PL and Hughes SH (1995) Analysis of mutations at position 184 in reverse transcriptase of HIV-1. Antimicrob Agents Chemother 39:1624-1628.
6. Cherrington JM, Allen SJW, Bischofberger N, and Chen MS (1995) Kinetic interaction of the diphosphates of 9-(2-phosphonylmethoxyethyl) adenine and other anti-HIV active purine congeners with HIV reverse transcriptase and human DNA polymerases a, b and g. Antivir Chem Chemother 6:217-221.
7. Cherrington JM, Fuller MD, Mulato AS, Allen SJ, Kunder SC, Ussery MA, Lesnikowski Z, Schinazi RF, Sommadossi JP, and Chen MS (1996a) Comparative kinetic analyses of interaction of inhibitors with Rauscher marine leukemia virus and human immunodeficiency virus reverse transcriptases. Antimicrob Agents Chemother 40:1270-1273.
8. Cherrington JM, Mulato AS, Fuller MD, and Chen MS (1996b) Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl] adenine in vitro. Antimicrob Agents Chemother 40:2212-2216.
9. Cihlar T, Fuller MD, and Cherrington JM (1997) Expression of the catalytic subunit (UL54) and the accessory protein (UL44) of human cytomegalovirus DNA polymerase in a coupled in vitro transcription/translation system. Protein Expr Purif 11:209-218.
10. De Clercq E, Holy A, Rosenberg I, Sakuma T, Balzarini J, and Maudgal PC (1986) A novel selective broad-spectrum anti-DNA virus agent. Nature (Lond) 323:464-467.
11. De Clercq E, Sakuma T, Baba M, Pauwels R, Balzarini J, Rosenberg I, and Holy A (1987) Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antivir Res 8:261-272.
12. de Jong MD, Vella S, Carr A, Boucher CA, Imrie A, French M, Hoy J, Sorice S, Pauluzzi S, Chiodo F, Weverling GJ, van der Ende ME, Frissen PJ, Weigel HM, Kauffmann RH, Lange JM, Yoon R, Moroni M, Hoenderdos E, Leitz G, Cooper DA, Hall D, Reiss P (1997) High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication. J Infect Dis 175:966-970.
13. Deeks SG, Collier A, Lalezari J, Pavia A, Rodrigue D, Drew WL, Toole J, Jaffe HS, Mulato AS, Lamy PD, Li W, Cherrington JM, Hellmann N, Kahn J (1997) The safety and efficacy of adefovir dipivoxil, a novel anti-HIV therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. J Infect Dis 176:1517-1523.
14. Gu Z, Fletcher RS, Arts EJ, Wainberg MA, and Parniak MA (1994a) The K65R mutant reverse transcriptase of HIV-1 cross-resistant to ddC, 3TC and ddI shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro. J Biol Chem 269:28118-28122.
15. Gu Z, Gao Q, Fang H, Salomon H, Parniak MA, Goldberg E, Cameron J, and Wainberg MA (1994b) Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes HIV resistance to 3TC and ddC. Antimicrob Agents Chemother 38:275-281.
16. Gu Z, Gao Q, Li X, Parniak MA, and Wainberg MA (1992) Novel mutation in the HIV-1 reverse transcriptase gene that encodes cross-resistance to ddI and ddC. J Virol 66:7128-7135.
17. Gu Z, Salomon H, Cherrington JM, Mulato AS, Chen MS, Yarchoan R, Foli A, Sogocio KM, and Wainberg MA (1995) K65R mutation of HIV-1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob Agents Chemother 39:1888-1891.
18. Hansen J, Schulze T, and Moellin K (1987) RNase H activity associated with bacterially expressed reverse transcriptase of human T-cell tropic virus III/ lymphadenopathy-associated virus. J Biol Chem 262:12393-12396.
19. Klarmann GJ, Schauber CA, and Preston BD (1993) Template-driven pausing of DNA synthesis by HIV-1 reverse transcriptase during polymerization of HIV-1 sequences in vitro. J Biol Chem 268:9793-9802.
20. Kozal MJ, Kroodsma K, Winters MA, Shafer RW, Efron B, Katzenstein DA, and Merigan TC (1994) Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Ann Intern Med 121:263-268.
21. Larder BA, Darby AG, and Richman DD (1989) HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science (Washington DC) 243:1731-1734.
22. Lin P-F, Samanta H, Rose RE, Patick AK, Trimble J, Bechtold CM, Revie DR, Khan NC, Federici ME, Li H, Lee A, Anderson RE, and Colonno RJ (1994) Genotypic and phenotypic analysis of HIV-1 isolates from patients on prolonged stavudine therapy. J Infect Dis 170:1157-1164.
23. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, and Kingsley LA (1996) Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science (Washington DC) 272:1167-1170.
24. Mulato AS, Lamy PD, Miller MD, Li W-X, Anton KE, Hellmann NS, and Cherrington JM (1998) Genotypic and phenotypic characterization of HIV-1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy. Antimicrob Agents Chemother, in press.
25. O'Brien WA, Hartigan PM, Daar ES, Simberkoff MS, and Hamilton JD (1997) Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure: VA Cooperative Study Group on AIDS. Ann Intern Med 126:939-945.
26. Pauwels R, Balzarini J, Schols D, Baba M, Desmyter J, Rosenberg I, Holy A, De Clercq E (1988) Phosphonylmethoxyethyl purine derivatives, a new class of anti-HIV agents. Antimicrob Agents Chemother 32:1025-1030.
27. Perno CF, Balestra E, Aquaro S, Panti S, Cenci A, Lazzarino G, Tavazzi B, Di Pierro D, Balzarini J, and Calio R (1996) Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethyl) adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines. Mol Pharmacol 50:359-366.
28. Quan Y, Gu Z, Li X, Li Z, Morrow CD, and Wainberg MA (1996) Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)2′-dideoxy-3′-thiacytidine by mutated M184V HIV-1. J Virol 70:5642-5645.
29. Robbins BL, Greenhaw J, Connelly MC, and Fridland A (1995) Metabolic pathways for activation of the antiviral agent 9-(2-phosphonyl-methoxyethyl)adenine in human lymphoid cells. Antimicrob Agents Chemother 39:2304-2308.
30. Rooke R, Tremblay M, Soudeyns H, De Stephano L, Yao XJ, Fanning M, Montaner JS, O'Shaughnessy M, Gelmon K, Tsoukas C, Ruedy H, and Wainberg MA (1989) Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy: Canadian Zidovudine Multi-Centre Study Group. AIDS 3:411-415.
31. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, Danner SA, Mulder J, Loveday C, Christopherson C, Kwok S, Sninsley J, and Boocher CAB (1995) Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 171:1411-1419.
32. Sharma PL and Crumpacker CS (1997) Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation. J Virol 71:8846-8851.
33. Shirasaka T, Chokekijchai S, Yamada A, Gosselin G, Imbach JL, and Mitsuya H (1995) Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells. Antimicrob Agents Chemother 39:2555-2559.
34. Tsai C-C, Follis KE, Sabo A, Grant RF, Bartz C, Nolte RE, Benveniste RE, and Bischofberger N (1994) Preexposure prophylaxis with 9-(2-phosphonylmethoxy-ethyl)adenine against SIV infection in macaques. J Infect Dis 169:260-266.
35. Ueno T and Mitsuya H (1997) Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2′,3′-dideoxynucleotide analogs using the single-nucleotide incorporation assay. Biochemistry 36:1092-1099.
36. Wainberg MA, Salomon H, Gu Z, Montaner JSG, Cooley TP, McCaffrey R, Ruedy J, Hirst HM, Cammack N, Cameron J, (1995) Development of HIV-1 resistance to 3TC in patients with AIDS or advanced AIDS-related complex. AIDS 9:351-357.
37. Winters MA, Shafer RW, Jellinger RA, Mamtora G, Gingeras T, and Merigan TC (1997) HIV-1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother 41:757-762.
38. Yokota T, Konno K, Shigeta S, Holy A, Balzarini J, and De Clercq E (1994) Inhibitory effects of acyclic nucleoside phosphonate analogues in hepatitis B virus DNA synthesis in HB611 cells. Antivir Chem Chemother 5:57-63.
39. Zazzi M, Catucci M, De Milito A, Romano L, Venturi G, Almi P, Gonnelli A, Rubino M, and Valensin PE (1996) Zidovudine resistance mutations and human immunodeficiency virus type 1 DNA burden: longitudinal evaluation of six patients under treatment. Infection 24:419-425.
40. Zhang D, Caliendo AM, Eron JJ, De Vore KM, Kaplan JC, Hirsch MS, and D'Aquila RT (1994) Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 38:282-287.